MS Speaks

Multiple Sclerosis => MS - RESEARCH AND NEWS => Topic started by: agate on September 01, 2018, 12:24:30 pm

Title: (Abst.) Phase 2b trial comparing 3 neuroprotective drugs in SPMS
Post by: agate on September 01, 2018, 12:24:30 pm
From PubMed, September 1, 2018--the announcement of a new study, "Multiple sclerosis--secondary progressive multi-arm randomisation trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in SPMS."


The drugs are "amiloride (acid-sensing ion channel antagonist); fluoxetine (selective serotonin reuptake inhibitor); and riluzole (glutamate antagonist)."  Fluoxetine is also known as Prozac or Sarafem. Miloride's brand name is Midamor. Riluzole is marketed as Rilutek and Teglutik and has been used to treat ALS (amyotrophic lateral sclerosis).


https://www.ncbi.nlm.nih.gov/pubmed/30166303